Skip to content

Study · Randomized controlled trial · n = 62 · 2017

4 results

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.

Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Dickson J, Li Y, Aviles-Olmos I and 6 more

Show all authors

Warner TT, Limousin P, Lees AJ, Greig NH, Tebbs S, Foltynie T

Lancet (London, England)3 Aug 2017Cited by 719 (Europe PMC)

PMID28781108 (opens in a new tab)PMCIDPMC5831666 (opens in a new tab)DOI10.1016/s0140-6736(17)31585-4 (opens in a new tab)PepBankPUB-28781108
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In Parkinson's disease, exenatide improved off-medication motor scores versus placebo at 60 weeks.

    In plain wordsIn Parkinson’s disease, exenatide improved movement scores assessed off dopaminergic medication versus placebo at 60 weeks.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseOff-medication MDS-UPDRS motor score at 60 weeks
    Study

    n = 60

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    2 mg once weekly · subcutaneous · 48 weeksAs given in this study (human).

    Measurements

    Change in off-medication MDS-UPDRS part 3 score
    −1 points
    exenatide group (improved)
    Change in off-medication MDS-UPDRS part 3 score
    2.1 points
    placebo group (worsened)
    Adjusted mean difference
    −3.5 points
    exenatide versus placebo

    Source sentences

    Summary
    At 60 weeks, off-medication scores on part 3 of the MDS-UPDRS had improved by 1·0 points (95% CI -2·6 to 0·7) in the exenatide group and worsened by 2·1 points (-0·6 to 4·8) in the placebo group, an adjusted mean difference of -3·5 points (-6·7 to -0·3; p=0·0318).
    2 context sentences
    Summary · context
    Our primary analysis included 31 patients in the exenatide group and 29 patients in the placebo group.
    Summary · context
    In this single-centre, randomised, double-blind, placebo-controlled trial, patients with moderate Parkinson's disease were randomly assigned (1:1) to receive subcutaneous injections of exenatide 2 mg or placebo once weekly for 48 weeks in addition to their regular medication, followed by a 12-week washout period.
  2. 02HumanRandomized controlled trialSafety outcome

    In Parkinson's disease, six serious adverse events occurred with exenatide versus two with placebo, with none judged intervention-related.

    In plain wordsIn Parkinson's disease, six serious adverse events occurred with exenatide versus two with placebo. None were judged treatment-related.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseSerious adverse events
    Study

    n = 62

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    2 mg once weekly · subcutaneous · 48 weeksAs given in this study (human).

    Measurements

    Serious adverse events
    6 events
    exenatide
    Serious adverse events
    2 events
    placebo

    Source sentences

    Summary
    Six serious adverse events occurred in the exenatide group and two in the placebo group, although none in either group were judged to be related to the study interventions.
    1 context sentence
    Summary · context
    In this single-centre, randomised, double-blind, placebo-controlled trial, patients with moderate Parkinson's disease were randomly assigned (1:1) to receive subcutaneous injections of exenatide 2 mg or placebo once weekly for 48 weeks in addition to their regular medication, followed by a 12-week washout period.
  3. 03HumanRandomized controlled trialSafety outcome

    In Parkinson's disease, injection-site reactions were common with both exenatide and placebo.

    In plain wordsIn Parkinson's disease, injection-site reactions were common with both exenatide and placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Direction not reportedInjection-site reactions
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Skin and wound
    Studied dose
    2 mg once weekly · subcutaneous · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    Injection site reactions and gastrointestinal symptoms were common adverse events in both groups.
    1 context sentence
    Summary · context
    In this single-centre, randomised, double-blind, placebo-controlled trial, patients with moderate Parkinson's disease were randomly assigned (1:1) to receive subcutaneous injections of exenatide 2 mg or placebo once weekly for 48 weeks in addition to their regular medication, followed by a 12-week washout period.
  4. 04HumanRandomized controlled trialSafety outcome

    In Parkinson's disease, gastrointestinal symptoms were common with both exenatide and placebo.

    In plain wordsIn Parkinson's disease, digestive symptoms were common with both exenatide and placebo.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Direction not reportedGastrointestinal symptoms
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    2 mg once weekly · subcutaneous · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    Injection site reactions and gastrointestinal symptoms were common adverse events in both groups.
    1 context sentence
    Summary · context
    In this single-centre, randomised, double-blind, placebo-controlled trial, patients with moderate Parkinson's disease were randomly assigned (1:1) to receive subcutaneous injections of exenatide 2 mg or placebo once weekly for 48 weeks in addition to their regular medication, followed by a 12-week washout period.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT04431713

Exenatide Once-weekly as a Treatment for Multiple System Atrophy

University College, Londonn = 5016 Sept 2020 to 22 Mar 2024

Multiple System Atrophy

Trial pageClinicalTrials.govUpdated 27 Jun 2025
CompletedPhase 2NCT01971242

Trial of Exenatide for Parkinson's Disease

University College, Londonn = 60Jun 2014 to Aug 2016

Parkinson's Disease

Trial pageClinicalTrials.govUpdated 17 Nov 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.